# A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy

> **NCT00261677** · PHASE3 · COMPLETED · sponsor: **Ortho Biotech Products, L.P.** · enrollment: 224 (actual)

## Conditions studied

- Anemia
- Hodgkin Disease
- Leukemia
- Lymphoma, Non-hodgkin

## Interventions

- **DRUG:** epoetin alfa

## Key facts

- **NCT ID:** NCT00261677
- **Lead sponsor:** Ortho Biotech Products, L.P.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-08
- **Primary completion:** —
- **Final completion:** 2003-10
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2011-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00261677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00261677, "A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00261677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*